trometry. Results: Bacterial profiling showed greater Bifidobacterium (15.1%) and Lactobacillus (4.2%) during supplementation compared to the control group (4.0% and 0%, respectively). While Lactobacillus became reduced after the probiotic had been stopped, Bifidobacterium remained high following discharge, suggestive of successful colonisation. qPCR analysis showed a significant increase (p ≤ 0.01) in B. bifidum in infants who received probiotic treatment compared to controls, but no significant increase was observed for L. acidophilus (p = 0.153). Metabolite profiling showed clustering based on receiving probiotic or matched controls, with distinct metabolites associated with probiotic administration. Conclusions: Probiotic species successfully colonise the preterm gut, reducing the relative abundance of potentially pathogenic bacteria, and effecting gut functioning. Bifidobacterium (but not Lactobacillus ) colonised the gut in the long term, suggesting the possibility that therapeutically administered probiotics may continue to exert important functional effects on gut microbial communities in early infancy.
Introduction
Probiotics are live micro-organisms which when administered in an appropriate amount will confer a health benefit to the host [1] . Globally Lactobacillus spp . and Bifidobacterium spp. are most commonly used [2] . For preterm infants, probiotic use has focused on potential reduction in necrotising enterocolitis (NEC) and late-onset sepsis [3] , but other important outcomes (feed tolerance, asthma, allergy) may be relevant [4] . Evidence from more than 20 randomised controlled trials suggests probiotics reduce NEC [5] . Meta-analysis shows a relative risk of 0.43 (95% CI 0.33-0.56) for NEC, and no impact on late onset sepsis (relative risk 0.91, 95% CI 0.8-1.03) [6] .
Mechanisms of probiotic action in preterm infants are multiple and complex and include potential competition with pathogenic bacteria in the gut ecosystem, direct effects on naive host immune mechanisms and enhancing intestinal maturation [7] , including enhancing tight junction integrity [2] . While a single causative agent is unlikely to be identified, dysbiosis of the gut microbiome preceding NEC may be important [7] [8] [9] [10] .
We aimed to conduct a longitudinal examination of extremely preterm infants through a neonatal intensive care unit (NICU) and after discharge to determine the effects of therapeutic exposure to the probiotic Infloran ® ( Bifidobacterium bifidum -ATCC15696 and Lactobacillus acidophilus -NCIMB701748). We explored changes in the overall bacterial community (16S rRNA profiling) and accurately quantified the probiotic species by quantitative PCR (qPCR). In addition, ultra-performance liquid chromatography mass spectrometry tandem mass spectrometry (UPLC-MS/MS) stool metabolomic profiling was undertaken to ascertain whether probiotic administration resulted in functional shifts at the metabolite level.
Methods

Study Design
Ethics approval was obtained from the County Durham and Tees Valley Research Ethics Committee, and parents gave signed consent for stool and data collection.
Infloran was introduced with the aim of giving it to all infants <32 weeks gestation soon after initial introduction of feeds until 34 weeks corrected. Half an Infloran capsule was given twice daily, equating to 125 mg b.d. at 10 9 organisms per dose. All were born within 3 months: we also identified a small number of infants who met the criteria but did not receive probiotics, providing an opportunity to explore cross-colonisation of probiotic strains within the NICU. Overall, 88 stools were analysed from 10 patients (7 probiotic and 3 controls). Of these, 60 were from probiotic-exposed infants [10 before, 32 during, 14 after exposure and 4 postdischarge (PD) samples], and 28 were from day of life matched control infants. All samples underwent 16S bacterial profiling, and of these a representative subset underwent qPCR (n = 75; 50 probiotic, i.e. 5 before, 30 during, 11 after exposure and 4 PD samples, and 25 control). All samples where sufficient stool remained also underwent metabolomic profiling (n = 40; 28 probiotic, i.e. 1 before, 17 during, 6 after exposure and 4 PD samples, and 12 control). This number of samples compares favourably with previous work and allows gut profiles to be confidently discriminated [10, 11] . All patients received maternal breast milk; additional demographics and sampling in relation to probiotic exposure and age are summarised in table 1 . 
Analysis of Faecal Microbiota Composition by 16S Bacterial
Analysis of L. acidophilus and B. bifidum by qPCR
To generate standard curves, PCR products (online suppl. table 1; see www.karger.com/doi/10.1159/000442936 for all online suppl. material) were cleaned using Exo-SAP-IT and cloned into pGEM-T easy vector (Promega) and expressed in Escherichia coli K12 cells [13, 14] . Plasmid DNA was extracted using the PureYield TM Plasmid Miniprep kit (Promega) and quantified using NanoDrop 1000 (Thermo Scientific). Absolute quantification was carried out in a CFX96 (Bio-Rad) using ABsolute QPCR SYBR Green mix (Thermo Scientific) in a total volume of 20 μl.
Metabolomic Profiling
Water, methanol, and acetonitrile (ACN) were liquid chromatography mass spectrometry grade (Sigma-Aldrich). Metabolites were extracted from 100 mg stool and homogenised in cold 80% methanol by vortexing for 15 min at 4 ° C. The suspension was then centrifuged at 10,000 g for 10 min at 4 ° C and lyophilised. Samples were resuspended in 1 ml and diluted a further 1: 1 in initial start phase buffer (5% ACN).
Stool metabolite profiling was performed using reverse-phase UPLC-MS/MS. An Accucore C 18 column (2.6 μm, 150 × 2.1 mm) was used at 40 ° C with a 3.0-μl injection and 300 μl/min flow rate throughout. A multi-step liquid chomatography gradient was used with 5% ACN increasing to 95% ACN over 22 min, with a further 95% ACN for 4 min followed by a final 4-min re-equilibration at 5% ACN. Samples were run in triplicate and the order in each triplicate sequence was randomised. A Q-Exactive (Thermo) was used for the MS and subsequent data-dependent MS/MS. Metabolomic profiling was performed using HESI with high-resolution (70,000) positive and negative switching. The mass range was set from 100 to 1,000 m/z. SIEVE (version 2.2 beta) was used to process the Thermo RAW files by component extraction. All blanks were used in background subtraction. Positive and negative data were processed individually and combined prior to downstream analysis.
Statistical Analysis
The bacterial profiles were analysed by multivariate partial least squares discriminant analysis (PLS-DA), and the metabolite profiles underwent orthogonal PLS-DA (OPLS-DA) using SIMCA 13.0 (Umetrics, Stockholm, Sweden) [15] . All variables, either operational taxonomic unit (OTU) or component, were automatically transformed within SIEVE. To check that data was adhering to multivariate normalities, Hotelling's T 2 tolerance limits were calculated and set at 0.95. Only variables >1 in the variable importance plot were included from the important variables plot [16] . Analysis of variance was used to determine whether numbers of L. acidophilus and B. bifidum (qPCR) increased during probiotic treatment with post hoc Tukey's test applied for multiple pairwise comparisons (Minitab 16).
Results
16S Bacterial Profiling of the Gut Microbiota
Infants exposed to Infloran had distinct gut microbiota profiles compared to controls ( fig. 1 a) . Using >97% similarity cut-off applied in determining OTUs, 3 different OTUs identified as Lactobacillus and 1 Bifidobacterium OTU were associated with current probiotic exposure ( fig. 1 b) . Most of the Lactobacillus spp. had the highest abundance during probiotic treatment, but these OTUs persisted after probiotic treatment had stopped. No Lactobacillus OTUs associated with probiotic administration were detected in controls and 1 Lactobacillus OTU was present at 0.1% relative abundance in the PD samples ( table 2 ; online suppl. fig. 1 ). In contrast, the abundance of Bifidobacterium was relatively high before probiotic supplementation (11.1%) and in controls (4.0%), but the relative abundance of this OTU increased significantly (p = 0.01) during probiotic administration to 15.0%, and then no significant change in the relative abundance was shown following (19.1%) probiotic administration in treated infants and after discharge (14.2%). While the gut microbiota was distinct between patients receiving probiotics and controls (R2Y = 0.85, Q2 = 0.60), the gut microbiota within patients remained relatively comparable while receiving probiotics (R2Y = 0.36, Q2 = 0.27), compared to before (R2Y = 0.18, Q2 = 0.02) and after (R2Y = 0.25, Q2 = 0.09). Here R2Y represents how well the variable is explained, and Q2 represents how well the variable is predicted, thus demonstrating addition of probiotic OTUs, rather than large shifts in the overall gut microbiota, as a result of probiotic administration.
The OTUs associated with control samples included a Clostridium (3.84% in controls compared with 0.47% in The Shannon diversity of the control group was higher than that of the probiotic group, with the samples during probiotic treatment being significantly lower (p ≤ 0.001; fig. 2 ). Within the probiotic groups the Shannon diversity increased across time. All groups had a significantly lower (p ≤ 0.001) diversity compared to the PD samples.
Quantification of B. bifidum-ATCC15696 and L. acidophilus-NCIMB701748 by qPCR
In accordance with the OTU data, the B. bifidum load (i.e. copy number of this species) was significantly (p ≤ 0.001) higher at all time points following administration of probiotic ( fig. 3 a) . B. bifidum was only detected in 1 probiotic-treated infant before administration and was not detected in any control infants ever. L. acidophilus , fig. 1b) . 
(For legend see next page.)
Color version available online the reported strain in Infloran, was only detected in quantifiable levels in 2 samples during probiotic administration and in 3 control samples ( fig. 3 b) .
Metabolomic Profiling of the Gut Microbiota
Overall, metabolite profiles demonstrated comparably more uniformity than bacterial profiles. The PD samples were found to have a distinct metabolite profile when compared with NICU samples by OPLS-DA (R2Y = 0.99, Q2 = 0.8), with a strong association of unique metabolites and metabolites present in much greater abundance compared with NICU samples (online suppl. fig. 2 ). Due to the inherently similar metabolomics profiles, OPLS-DA was unable to robustly separate samples taken during or after probiotic administration, and control groups ( fig. 4 a: R2Y = 0.62, Q2 = 0.31). However, following removal of metabolites with a variable importance plot of <1 (leaving only metabolites with large differences in the relative intensities), the groups could be separated more robustly ( fig. 4 b: R2Y = 0.80, Q2 = 0.56). The loadings plot showed a cluster of metabolites associated with samples during probiotic intake. Further study will be required to robustly identify these and other metabolites of interest using additional techniques or known standards.
Discussion
We explored the gut microbiota in preterm neonates receiving the probiotic Infloran and non-exposed contemporaneous controls. We also explored the persistence of effects after discharge of receiving probiotics in the NICU. Uniquely, both molecular sequencing and metabolomic profiling were performed to determine (1) overall changes to the gut microbiota as a result of probiotic receipt, (2) the quantification of the reported species in Infloran, (3) long-term colonisation, and (4) associated functional shifts in gut metabolites.
Supervised modelling demonstrated that infants receiving Infloran have a different gut microbiota to controls, where the probiotic genera used in this study (Bifidobacterium and Lactobacillus) were most associated with samples taken during probiotic receipt. During ongoing administration, such detection is not necessarily indicative of colonisation but may simply represent the passage of DNA from the administered species through the host [17] . However, by exploring persistence following administration ceased and after discharge we found the Bifidobacterium OTU associated with probiotic intake was able to successfully establish itself in the resident flora for the long term, with comparable levels after discharge as during active administration. In a recent publication by our group exploring PD samples from infants who existed in the NICU prior to the use of any probiotic, we found the average relative abundance of Bifidobacterium sp. was 5% following discharge [18] . In comparison, the PD samples from probiotic infants in this study constituted 14.16%, suggesting that the Bifidobacterium spp. remain viable after probiotic administration has been stopped for a long period of time. Further work is necessary to confirm this is a direct result of probiotic colonisation.
Bifidobacterium OTUs were present in control samples and before probiotic administration in the next-generation sequencing data, but the strain of B. bifidum used in the probiotic was not detected by qPCR in controls and was detected in only 1 'before' probiotic sample. While the next-generation sequencing and qPCR data were in agreement for B. bifidum , data were less comparable for L. acidophilus . By next-generation sequencing, Lactobacillus OTUs were not detected from controls, and scarcely detected before probiotics or after discharge. However, 3 Lactobacillus OTUs increased during and after probiotic, compared with control and PD samples. Multiple OTUs of Lactobacillus may represent issues in the bioinformatic alignment and identification, or the potential that more than one species of Lactobacillus was present in Infloran. The enhanced ability of Bifidobacterium to successfully colonise and proliferate with higher abundance and greater persistence compared to Lactobacillus is important. Increased colonisation by Bifidobacterium over Lactobacillus has previously been shown in one breastfed preterm population [19] , but opposing trends with increased colonisation by Lactobacillus have been shown for term neonates [20] .
Administration of probiotic did not significantly alter the total composition of gut microbiota, with most bacterial OTUs being detected in all samples. However, changes in the relative abundance of OTUs did occur in probiotic-treated infants, with an increased abundance of Bifidobacterium and Lactobacillus and notable decreases in the relative abundances of other taxa. The relatively high abundance of Staphylococcus spp. before probiotics were administered likely reflects high rates of caesarean delivery in probiotic infants [21, 22] . Organisms detected almost exclusively in controls included Acinetobacter, Actinomyces, Clostridium, and Streptococcus, agreeing with published data [19, 23] . Importantly, a significant reduction in organisms associated with NEC or late-onset sepsis, including Clostridium and Klebsiella , were found in probiotic-treated infants [24, 25] . However, an increasing abundance of E. coli was observed through the probiotic group, with the highest relative abundance found after probiotics were stopped. While E. coli typically represents a common commensal of the healthy gut microbiome, it has previously been shown to increase in a twin prior to NEC diagnosis compared to the concordant control twin [26] . Further work is needed to determine if potentially negative changes in certain species occur as a result of probiotic administration, such as preferential growth conditions to potential pathogens resulting from sugar monomers produced by B. bifidum [27] .
In accordance with a small number of published studies, the metabolomic profiles were more comparable and stable than bacterial profiles [9, 28] . Although the metabolomic profiles of probiotic infants were comparable to those of controls, certain metabolites were detected with significantly increased abundance during probiotic administration. None of these metabolites could be matched with our existing internal standards, and further work will be needed to identify these, determining whether they may be connected with potential regulatory pathways. The data presented are from a small number of infants contributing variable numbers of samples at different postnatal ages, but are well representative of results before, during and after probiotic administration. Despite the sampling limitations of our study, control infants did not acquire the probiotic species, thus significant cross-colonisation in our unit using this product seems uncommon.
In summary, probiotic species alter gut microbial communities during and after therapeutic administration, with Bifidobacterium but not Lactobacillus demonstrating long-term proliferation in this population. A reduction in the abundance of taxa such as Clostridium that have been associated with NEC may be relevant if, as the meta-analyses suggest, probiotics do reduce the occurrence of this serious disease. Multiple OTUs associated with Lactobacillus were detected, although qPCR was unable to robustly quantify the L. acidophilus used in the administered product, thus raising important quality assurance concerns around the use of commercially available products in a high-risk patient group. Exploring functional metabolite changes may provide important information on mechanisms of action of interventions such as probiotics, and should be considered for inclusion into future interventional trials.
